Impact News +++ United States Lime & Minerals Reports Third Quarter 2026 Results and Declares Regular Quarterly Cash... (GlobeNewswire EN) +++ UNITED STATES LIME Aktie -4,51%

OPKO HEALTH Aktie

>OPKO HEALTH Aktienkurs

1.48 EUR +1.4% (TradegateBSX)

Ask: 1.48 EUR / 1998 Stück

Bid: 1.45 EUR / 2051 Stück

Tagesumsatz: 3090 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

OPKO HEALTH Aktie über LYNX handeln

Intraday

1 Jahr

>OPKO HEALTH Performance

1 Woche: +2,8%

1 Monat: +3,9%

3 Monate: +28,1%

6 Monate: +54,6%

1 Jahr: +18,1%

laufendes Jahr: +34,5%

>OPKO HEALTH Aktie

Profil:

OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals. Through its Diagnostics segment, the company provides clinical laboratory and genetic testing services, including BioReference Health and specialized as..
>Volltext..

Insiderhandel:

>OPKO HEALTH Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>OPKO HEALTH Peer Group

Gesundheit, Nierenerkrankungen & -behandlung, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>OPKO HEALTH Chart & Kurs - NASDAQ

>OPKO HEALTH News

28.10.26 - 13:57

OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire EN)

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 on Wednesday, November 4, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance....

21.10.26 - 20:37	Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp (PR Newswire)
	MIAMI, Oct. 21, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised OPKO Health, Inc., a multinational biopharmaceutical company, on its agreement to sell select assets of its wholly owned subsidiary, BioReference Health, LLC, to Labcorp. The purchase price for the......

16.10.26 - 19:00	OPKO Health to Sell Select BioReference Assets to Labcorp for $722M (Zacks)
	OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test....

15.10.26 - 16:01	Opko Health-Aktie haussiert: Labcorp übernimmt BioReference-Sparten für bis zu 872 Millionen Dollar (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

15.10.26 - 15:30	Opko Health-Aktie nach 722-Millionen-Dollar-Verkauf von BioReference-Vermögenswerten im Höhenflug (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

15.10.26 - 15:21	Opko Health stock soars on $722M BioReference asset sale (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

15.10.26 - 13:33	Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health (PR Newswire)
	Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory......

28.09.26 - 19:45	Here′s Why You Should Retain OPK Stock in Your Portfolio for Now (Zacks)
	OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns....

10.09.26 - 16:31	OPKO Health: Strategiewechsel hin zu Therapeutika, gestützt durch hohe Liquidität (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.08.26 - 19:00	Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report? (Zacks)
	OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

19.08.26 - 20:30	Is OPK Worth Buying as Valuation Meets Improving Business Trends? (Zacks)
	OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced....

19.08.26 - 20:30	OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going? (Zacks)
	OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks....

19.08.26 - 20:30	OPK Raises $125 Million Against Royalties: What Investors Should Know (Zacks)
	OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China....

18.08.26 - 21:15	OPKO Health Secures $125 Million Financing Against Mazdutide Royalties (Zacks)
	OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside....

04.08.26 - 19:45	OPKO Health (OPK) Upgraded to Buy: Here′s What You Should Know (Zacks)
	OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

03.08.26 - 13:03	Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health (GlobeNewswire EN)
	Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026...

29.07.26 - 23:54	OPKO Health gives back 17% after sharp post-earnings surge (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.26 - 04:48	Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend? (RTTNews)
	Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue outlook on strong commercial momentum; and MapLight Therapeutics, which staged a sharp rebound after a recent selloff, among others....

29.07.26 - 00:24	Why Opko Health Stock Surged by 33% on Tuesday (Fool)
	It posted a beat-and-raise second quarter....

28.07.26 - 20:30	OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates (Zacks)
	OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Mancher Mann ist wie ein Brief: man sollte ihm eine kleben, bevor man ihn aufgibt. - Beate Hasenau

Partner: >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram